ILARIS 150 MG/ML SOLUCION INYECTABLE

( ARTG ) Periodic fever syndromes Ilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older: Cryopyrin-associated periodic syndromes Ilaris is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children aged 2 years or older including: Familial Cold Autoinflammatory Syndrome (FCAS) /Familial Cold Urticaria (FCU) Muckle-W‍‍‍‍‍‍​​​‍​​​​​​ells Syndrome (MWS) Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA). Tumour necrosis factor receptor associated periodic syndrome (TRAPS) Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS). Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD). Familial Mediterranean fever (FMF) Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate. Ilaris is also indicated for the treatment of: Systemic Juvenile Idiopathic Arthritis (sJIA) Ilaris is indicated for the treatment of active Systemic Juvenile Idiopathic Arthritis (sJIA) in patients aged 2 years or older.